Cite
Burkitt lymphoma – no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy.
MLA
Tan, Jing Yuan, et al. “Burkitt Lymphoma – No Impact of HIV Status on Outcomes with Rituximab-Based Chemoimmunotherapy.” Leukemia & Lymphoma, vol. 64, no. 3, Mar. 2023, pp. 586–96. EBSCOhost, https://doi.org/10.1080/10428194.2022.2027402.
APA
Tan, J. Y., Qiu, T. Y., Chiang, J., Tan, Y. H., Yang, V. S., Chang, E. W. Y., Poon, E., Somasundaram, N., Farid, M., Tao, M., Lim, S. T., & Chan, J. Y. (2023). Burkitt lymphoma – no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy. Leukemia & Lymphoma, 64(3), 586–596. https://doi.org/10.1080/10428194.2022.2027402
Chicago
Tan, Jing Yuan, Tian Yu Qiu, Jianbang Chiang, Ya Hwee Tan, Valerie Shiwen Yang, Esther Wei Yin Chang, Eileen Poon, et al. 2023. “Burkitt Lymphoma – No Impact of HIV Status on Outcomes with Rituximab-Based Chemoimmunotherapy.” Leukemia & Lymphoma 64 (3): 586–96. doi:10.1080/10428194.2022.2027402.